Credit Suisse analyst Richard Law assumed coverage of Editas Medicine with a Neutral rating and $13 price target. The analyst states that he is assuming a 70% probability of favorable final appeal ruling for Broad/MIT from the U.S. federal appeals court, which would give the company "monopolistic IP control of CRISPR/Cas9 editing in the U.S." Law further notes that he assigns "little value" to Editas’ lead asset EDIT-301 as he does not believe that the company could demonstrate differentiated benefits that are "clinically meaningful".
Published first on TheFly
Read More on EDIT:
- Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
- Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
- Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
- Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting